|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and statins were of statistical significance for stroke risks.The majority of AF patients post-RFAs was of high stroke risk and received warfarin thromboprophylaxis in accordance with national guidelines.
|
29381974 |
2017 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Classic RAS blockers such as angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent AF by affecting the accumulation of the EAT, representing a useful therapeutic strategy for preventing AF especially in patients with heart failure and known left ventricular dysfunction.
|
31375968 |
2020 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Blockade of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARB) has been shown to decrease incident atrial fibrillation (AF).
|
30057228 |
2018 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population.
|
18496132 |
2008 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen a-20c genotype alone and in combination with ACE I/D genotype predicts an increased risk of atrial fibrillation.
|
18496132 |
2008 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
An ACE-dependent increase in the amounts of activated Erk1/Erk2 in atrial interstitial cells may contribute as a molecular mechanism for the development of atrial fibrosis in patients with AF.
|
10807475 |
2000 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although activation of the renin-angiotensin-aldosterone system (RAAS) now appears to play a role in the pathophysiology of atrial fibrillation (AF), it remains to be determined if ACE genotype impacts response to conventional AAD therapy in patients with AF.
|
17556195 |
2007 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Age, smoking history, diabetes mellitus,hypertension frequency, angiotensin converting enzyme inhibitor-angiotensin receptor blocker use, CHA₂DS₂VASc and HAS-BLED scores, serum sST2 level, left atrium (LA) end-diastolic diameter, LA volume and LA volume index were related to AF recurrence.
|
30238709 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
After optimal up-titration of BBs and angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), mean HR in patients with AF was 73 ± 15 beats/minute (bpm), 36% had resting HR ≤65 bpm.
|
28393567 |
2017 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin-converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation.
|
30067937 |
2018 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation.
|
12687832 |
2003 |